NRX Pharmaceuticals (NRXP) Non-Current Assets (2017 - 2026)
NRX Pharmaceuticals (NRXP) posted quarterly Non-Current Assets of $4.5 million for Q1 2026, up 1259.88% year-over-year from $334000.0 in Q1 2025, and up 11.76% quarter-over-quarter from $4.1 million in Q4 2025.
NRX Pharmaceuticals (NRXP) Non-Current Assets (2017 - 2026) Analysis & Trends
NRX Pharmaceuticals (NRXP) has reported Non-Current Assets for 10 consecutive years, with $4.5 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Non-Current Assets rose 1259.88% year-over-year to $4.5 million; the TTM figure through Mar 2026 stood at $11.9 million (up 736.47% YoY), while the FY2025 annual figure was $4.1 million, up 1064.47% from the prior year.
- Non-Current Assets rose to $4.5 million in Q1 2026 per NRXP's latest filing, from $4.1 million in the prior quarter.
- Across five years, Non-Current Assets topped out at $4.5 million in Q1 2026 and bottomed at $17000.0 in Q1 2022.
- Historically, Non-Current Assets has averaged $843764.7 across 5 years, with a median of $334000.0 in 2025.
- Annual changes were most pronounced in 2022 — Non-Current Assets sank 99.72% — and 2023, when it soared 1952.38%.
- NRX Pharmaceuticals' Non-Current Assets stood at $21000.0 in 2022, then jumped by 1952.38% to $431000.0 in 2023, then slipped by 19.03% to $349000.0 in 2024, then surged by 1064.47% to $4.1 million in 2025, then advanced by 11.76% to $4.5 million in 2026.
- Business Quant data shows NRXP's Non-Current Assets at $4.5 million in Q1 2026, $4.1 million in Q4 2025, and $3.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 1.96 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 5.15 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 1.96 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 938.60 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 6.80 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 468.65 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 18.06 Bn |
| 10 | NRX Pharmaceuticals | 132.53 Mn | 105.83 Mn | 426,000.00 | 5.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 4.54 Mn |
| Dec 31, 2025 | 4.06 Mn |
| Sep 30, 2025 | 3.05 Mn |
| Jun 30, 2025 | 248,000.00 |
| Mar 31, 2025 | 334,000.00 |
| Dec 31, 2024 | 349,000.00 |
| Sep 30, 2024 | 356,000.00 |
| Jun 30, 2024 | 384,000.00 |
| Mar 31, 2024 | 441,000.00 |
| Dec 31, 2023 | 431,000.00 |
| Sep 30, 2023 | 21,000.00 |
| Jun 30, 2023 | 21,000.00 |
| Mar 31, 2023 | 24,000.00 |
| Dec 31, 2022 | 21,000.00 |
| Sep 30, 2022 | 23,000.00 |
| Jun 30, 2022 | 19,000.00 |
| Mar 31, 2022 | 17,000.00 |
| Dec 31, 2021 | 15,000.00 |
| Sep 30, 2021 | 15,921.00 |
| Jun 30, 2021 | 12,730.00 |